Depósitos de Calcio

Allicin, the primary bioactive organosulfur compound of garlic, has been identified in patent literature and a systematic review as a sulfation substrate and methyl donor for homocysteine clearance, functioning similarly to TMG. A 2021 systematic review confirmed garlic extract (of which allicin is the primary active component) significantly reduced homocysteine in animal studies.

Beetroot is one of the richest dietary sources of betaine (trimethylglycine), which acts as a methyl donor to convert homocysteine to methionine via the BHMT enzyme. Clinical meta-analyses confirm that betaine supplementation reliably reduces plasma homocysteine in healthy and at-risk individuals.

Betaine (trimethylglycine/TMG) directly remethylates homocysteine to methionine via the enzyme betaine-homocysteine methyltransferase (BHMT) in the liver and kidneys, independently of folate or B12. A 2013 meta-analysis of 5 RCTs found betaine supplementation (≥4 g/day) significantly reduced plasma homocysteine by a pooled 1.23 µmol/L. Betaine is also used medically (as Cystadane) for genetic homocystinuria.

Elevated homocysteine is a cardiovascular and neurological risk factor driven by deficiencies in B12, folate, and B6 — all of which are abundant in bovine liver. These three nutrients are the primary clinical interventions for hyperhomocysteinemia. Bovine liver provides all three cofactors required to lower homocysteine through both the remethylation and trans-sulfuration pathways.

Brussels sprouts are a meaningful dietary source of folate, which is the primary methyl-donor cofactor for the remethylation of homocysteine to methionine via the enzyme methionine synthase. Adequate dietary folate intake is recognized as a key strategy for maintaining normal circulating homocysteine levels.

Choline is an essential nutrient that serves as an indirect methyl donor for homocysteine remethylation: it is oxidized to betaine (TMG) in the liver, which then remethylates homocysteine via BHMT. Higher dietary choline intake is associated with lower circulating homocysteine concentrations. Choline deficiency raises homocysteine through impaired BHMT-pathway methylation.

Collard greens are among the richest natural sources of folate (dark leafy greens per WebMD), and folate is the primary dietary determinant of plasma homocysteine. Elevated homocysteine is an established biomarker for cardiovascular risk; dietary folate from vegetables has been shown in a controlled trial to significantly decrease plasma homocysteine concentrations in humans. WeightWatchers cites that collard greens' folate lowers blood levels of homocysteine, linked to heart disease and arterial hardening.

Creatine supplementation can lower plasma homocysteine by reducing the body's endogenous demand for creatine synthesis, which is one of the largest consumers of S-adenosylmethionine (SAM)–derived methyl groups. By sparing SAM from creatine synthesis, more methyl groups are available for homocysteine remethylation. Animal models and human data support this mechanism, with a specific RCT case study showing 5 g/day creatine reduced homocysteine by 49% in an MTHFR 677TT homozygote.

Creatine monohydrate is the most studied form of creatine for homocysteine modulation, reducing SAM methylation demand by suppressing endogenous creatine biosynthesis. Animal studies show ~25% lower plasma homocysteine; a human case study with 5 g/day for one month in an MTHFR 677TT individual showed a 49% reduction from 33.3 to 17.1 µmol/L. It is the creatine form used in the clinical trial registered for homocystinuria.

Curcumin (the active polyphenol of turmeric) has shown favorable effects on serum homocysteine in clinical trials. A 2021 systematic review (PMC8196702) covering animal studies and clinical trials found curcumin significantly reduced homocysteine in animal studies and showed favorable effects in human clinical trials, though with non-uniform results requiring further study.

DHA (docosahexaenoic acid) is an omega-3 fatty acid that has been shown to participate in homocysteine metabolism via phosphatidylcholine pathways and the PEMT enzyme. Meta-analyses of RCTs show omega-3 supplementation including DHA significantly reduces plasma homocysteine. DHA's interaction with homocysteine is clinically relevant to cognitive outcomes, particularly in older adults.

Dimethylglycine (DMG) is the immediate metabolic product formed when betaine (TMG) donates a methyl group to homocysteine via BHMT, remethylating it to methionine. DMG itself can serve as a methyl donor in subsequent one-carbon metabolism reactions and is used in supplements to support methylation. Its direct role in lowering homocysteine is secondary to betaine's, acting primarily as a methyl carrier in the BHMT pathway.

EPA is an omega-3 fatty acid that, alongside DHA, contributes to homocysteine-lowering effects demonstrated across multiple RCTs and meta-analyses. Meta-analyses confirm that combined EPA+DHA supplementation significantly reduces plasma homocysteine, with effects augmented by B vitamins. EPA also supports anti-inflammatory pathways relevant to hyperhomocysteinemia-induced endothelial injury.

Fava beans are one of the richest dietary sources of folate; one cup provides roughly 40–50% of the daily folate requirement. Folate is the primary dietary determinant of homocysteine remethylation, and higher folate intake is robustly associated with lower plasma homocysteine levels. A 7-day fava bean dietary intervention directly measured plasma homocysteine as an outcome.

FMN and FAD are obligate cofactors for methylenetetrahydrofolate reductase (MTHFR), the enzyme that converts homocysteine to methionine. Riboflavin (the FMN/FAD precursor) has been shown in randomized controlled trials to lower homocysteine specifically in individuals homozygous for the MTHFR 677C→T polymorphism. This effect is genotype-specific and not seen in wild-type individuals.

Folic acid is the most potent single nutrient for lowering plasma homocysteine, reducing levels by up to 25% in numerous RCTs. It acts as the primary methyl donor in the remethylation of homocysteine to methionine via the MTHFR enzyme. The HOPE-2 trial (n=5522) demonstrated a 2.4 µmol/L reduction in plasma homocysteine with folic acid plus B vitamins. US mandatory fortification since 1998 has demonstrably lowered population homocysteine levels.

Folinic acid lowers elevated homocysteine (hyperhomocysteinemia) by donating one-carbon units to remethylate homocysteine to methionine via the one-carbon/folate cycle. Clinical trials in hemodialysis patients show folinic acid reduces plasma homocysteine by approximately 22–44%. Its effect is broadly comparable to equimolar folic acid doses.

Garbanzo beans are a rich source of folate (vitamin B9), which is the primary dietary regulator of homocysteine metabolism. Adequate folate intake drives the remethylation of homocysteine to methionine via methionine synthase, lowering circulating homocysteine levels, a known independent risk factor for cardiovascular disease. Clinical nutrition literature consistently lists chickpea folate content as cardioprotective via this mechanism.

Garlic extract has demonstrated significant homocysteine reduction in animal studies, and allicin (garlic's active sulfur compound) is proposed to function as a sulfation substrate and methyl donor for homocysteine clearance, similar to TMG. A 2021 systematic review confirms garlic extract reduced homocysteine in animal studies, though clinical trial evidence is inconclusive.

Multiple RCTs and two independent meta-analyses confirm genistein supplementation significantly lowers plasma homocysteine levels. A meta-analysis of 8 RCTs (476 subjects) found a reduction of 0.58 µmol/L versus placebo. A later 2025 meta-analysis found a similar reduction of 0.74 µmol/L across 7 RCTs.

Intrinsic factor is a glycoprotein secreted by gastric parietal cells that is essential for the absorption of vitamin B12 in the terminal ileum. Since B12 deficiency directly causes elevated homocysteine through impaired methionine synthase activity, supplemental intrinsic factor is used to ensure adequate B12 absorption, particularly in individuals with pernicious anemia, elderly persons, or those with GI conditions.

L-cysteine is a direct metabolic product of homocysteine via the transsulfuration pathway: homocysteine is converted to cystathionine and then to cysteine by cystathionine beta-synthase and cystathionine gamma-lyase. Adequate cysteine availability supports flux through this pathway, helping to clear excess homocysteine. Elevated homocysteine is an established biomarker of cardiovascular risk.

L-methionine is the direct metabolic precursor to homocysteine; supplementation at 1,500 mg/day has been shown in a placebo-controlled crossover RCT to raise plasma homocysteine by ~2 µmol/L in both healthy controls and patients. High-dose methionine loading acutely impairs endothelial function via elevated homocysteine. B12 and folate co-supplementation can attenuate this rise.

L-serine is biochemically established as the principal one-carbon donor to the folate cycle, which regenerates methionine from homocysteine via methylation. Serine also participates directly in homocysteine catabolism through the transsulfuration pathway. Human isotope tracer studies confirm serine contributes approximately 100% of the one-carbon units for total body homocysteine remethylation under fasting conditions.

LEM and its bioactive compound eritadenine have been shown in animal studies to significantly reduce elevated serum homocysteine levels through inhibition of S-adenosyl-L-homocysteine hydrolase (SAH) and regulation of DNA methyltransferases. Evidence is currently limited to preclinical models.

Liquid liver fractions are a concentrated source of vitamin B12 and folate, the primary nutrients that regulate homocysteine via the remethylation pathway. B12 supplementation has been shown in a placebo-controlled RCT to significantly reduce serum homocysteine. Liver also supplies choline/betaine, which support the alternative BHMT remethylation pathway in the liver.

Methylcobalamin is the biologically active coenzyme form of vitamin B12 that directly participates in the methionine synthase reaction, converting homocysteine to methionine. It donates a methyl group to homocysteine via the 5-MTHF–methionine synthase pathway, making it directly effective for homocysteine lowering without requiring metabolic activation.

NAC may lower plasma homocysteine by displacing it from protein-bound forms and by serving as a cysteine precursor that supports the transsulfuration pathway toward glutathione synthesis. A small clinical study found that 4000 mg/day effervescent NAC for 2 weeks lowered homocysteine levels by 45% vs. placebo. The Linus Pauling Institute and other authorities identify NAC as a supportive agent in homocysteine metabolism.

Omega-3 fatty acids (EPA and DHA) have been shown in multiple RCTs and a meta-analysis to lower plasma homocysteine levels. A 2022 meta-analysis of 20 RCTs (2676 participants) found omega-3 supplementation significantly reduced plasma homocysteine by a weighted mean difference of 1.34 µmol/L. Their effect is enhanced when combined with B vitamins.

Pyridoxal-5-Phosphate (P-5-P) is the biologically active coenzyme form of vitamin B6 that directly catalyzes the transsulfuration of homocysteine. As a cofactor for cystathionine beta-synthase, P-5-P initiates the irreversible clearance of homocysteine via conversion to cystathionine and then cysteine. P-5-P deficiency is independently associated with hyperhomocysteinemia.

Parsley is a rich source of folate, which is the primary dietary regulator of homocysteine metabolism. Elevated homocysteine is a recognised cardiovascular risk factor, and folate supplementation is well-established to lower plasma homocysteine. Parsley's folate content supports this mechanism at culinary doses.

PC provides choline, which is oxidized to betaine—a methyl donor that remethylates homocysteine to methionine. Controlled clinical studies show that PC supplementation significantly lowers fasting and post-methionine-load plasma homocysteine in healthy men. The PEMT pathway for endogenous PC synthesis is also a significant source of homocysteine.

Resveratrol is a polyphenol stilbene that has shown favorable effects on serum homocysteine in clinical trials, according to a 2021 systematic review (PMC8196702). Both animal studies and clinical trials demonstrate homocysteine-lowering effects, though results are not uniform across all studies. Resveratrol's mechanism may involve activation of SIRT1 and modulation of methylation pathways.

SAMe (S-adenosylmethionine) is the body's primary methyl donor, generated from methionine (itself produced from homocysteine remethylation). Supplementing with SAMe can support the transsulfuration of homocysteine to cysteine and downstream to glutathione. Multiple authoritative sources including the Linus Pauling Institute and Life Extension identify SAMe as supporting homocysteine metabolism.

Spinach is among the richest dietary sources of folate. Folate drives the methylation of homocysteine to methionine, lowering circulating homocysteine levels. A 13-week RCT confirmed that a folate-rich diet reduced homocysteine by ~20%, comparable to synthetic folate supplementation.

Taurine supplementation has been shown in a controlled clinical study to significantly lower plasma homocysteine in healthy middle-aged women, reducing levels from 8.5 to 7.6 µmol/L (p<0.05) with 3 g/day for 4 weeks. The proposed mechanism involves taurine blocking methionine absorption and redirecting homocysteine flux toward cysteine production. Evidence is limited and mixed.

TMG (trimethylglycine), identical to betaine anhydrous, is the primary non-B-vitamin methyl donor for homocysteine remethylation via the BHMT enzyme in the liver. Meta-analysis of 5 RCTs confirms it reliably lowers plasma homocysteine at 4–6 g/day. It is used medically in genetic homocystinuria and is recognized in multiple authoritative nutrition references.

Vitamin B12 (cobalamin) is an essential cofactor for methionine synthase, the enzyme that remethylates homocysteine to methionine using 5-methyltetrahydrofolate. B12 deficiency directly elevates homocysteine. Supplementation with at least 0.4 mg B12 daily lowers homocysteine by approximately 7% as a standalone effect, with greater reductions in combination with folate and B6.

Riboflavin (vitamin B2) is an essential cofactor for MTHFR, the enzyme that generates 5-MTHF for homocysteine remethylation, and for methionine synthase reductase (MTRR). B2 deficiency impairs both pathways and raises homocysteine. Riboflavin supplementation specifically lowers homocysteine in individuals homozygous for the MTHFR 677C>T polymorphism, as demonstrated in RCTs published in Circulation.

Vitamin B6 (pyridoxine), as its active form pyridoxal-5-phosphate, is the cofactor for cystathionine beta-synthase (CBS), the enzyme that initiates the transsulfuration pathway converting homocysteine to cystathionine and then cysteine. While B6 alone does not reliably lower fasting homocysteine, it is critical for post-methionine-load homocysteine clearance and acts synergistically with folate and B12.

Folate is the naturally occurring form of vitamin B9 and the principal nutrient involved in homocysteine remethylation. As 5-methyltetrahydrofolate, it donates a methyl group to convert homocysteine to methionine. Numerous RCTs confirm folate supplementation significantly reduces plasma homocysteine; Linus Pauling Institute designates folate as a primary nutrient for homocysteine metabolism.

Methylfolate (5-MTHF) is the bioactive form of folate that directly participates in homocysteine remethylation without requiring metabolic conversion by MTHFR. It is particularly important for individuals with MTHFR polymorphisms who cannot efficiently convert folic acid to its active form. Clinical evidence strongly supports its role in lowering plasma homocysteine.

Wheat germ is a meaningful dietary source of folate (vitamin B9) and vitamin B6, both of which are required for homocysteine remethylation and transsulfuration pathways. Elevated homocysteine is a cardiovascular risk factor and is reduced by adequate folate and B6 intake. A wheat aleurone RCT specifically measured plasma homocysteine as a primary outcome.

Zinc acts as a cofactor supporting the liver's betaine-homocysteine methyltransferase (BHMT) enzyme system that remethylates homocysteine to methionine. The Food For The Brain Foundation specifically identifies zinc as supporting the conversion of homocysteine in the liver via SAMe generation. Low zinc status has been associated with elevated homocysteine in observational studies.